Viking Therapeutics (VKTX) Current Assets (2014 - 2026)

Viking Therapeutics has disclosed Current Assets across 13 years of filings, most recently posting $517.6 million for Q2 2026.

• In Q2 2026, Current Assets fell 37.42% year-over-year to $517.6 million; the TTM figure through Jun 2026 stood at $517.6 million (down 37.42% YoY), while the FY2025 annual figure was $715.6 million, down 21.12% from the prior year.
• Current Assets came in at $517.6 million for Q2 2026 at Viking Therapeutics, down from $608.2 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $966.3 million in Q1 2024 to a low of $149.5 million in Q1 2023.
• Average Current Assets over 5 years is $557.3 million, with a median of $562.9 million recorded in 2026.
• Year-over-year, Current Assets surged 546.52% in 2024 and plunged 37.42% in 2026.
• Over 5 years, Current Assets stood at $167.0 million in 2022, then jumped by 119.84% to $367.2 million in 2023, then surged by 147.05% to $907.2 million in 2024, then decreased by 21.12% to $715.6 million in 2025, then slipped by 27.67% to $517.6 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $517.6 million in Q2 2026, $608.2 million in Q1 2026, and $715.6 million in Q4 2025.